Bavarian Nordic AS
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
1.36%
Market Cap
1.90 Bil.
P/E Ratio
10.83
Dividend Yield
0.00 %
Earnings per Share
2.37 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 24.64 G | 0 Units |
| PRICE DETERMINATION TIME | 06/12/2026 / 09:56:39 PM | |
| DAILY VOLUME (UNITS) | 50 | |
| DAILY HIGH / LOW | 24.98 | 24.5 |
| PREV. DAY'S PRICE | 24.92 | (06/11) |
| CHANGE DAY BEFORE | -0.28 | -1.12 % |
| 52 WEEK HIGH / LOW | 32.76 (10/15) | 22.18 (06/23) |
Key Figures (in EUR)
| 2027e | 2026e | 2025 | 2024 | 2023 | |
|---|---|---|---|---|---|
| EARNINGS PER SHARE | 1.33 | 1.34 | 2.37 | 1.70 | 2.58 |
| DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| DIVIDEND YIELD IN % | - | - | 0.00 % | 0.00 % | 0.00 % |
| DIVIDEND GROWTH IN % | - | - | - | - | - |
| PRICE - EARNINGS RATIO | 18.58 | 18.43 | 10.83 | 14.97 | 9.23 |
| PRICE - BOOK RATIO | - | - | 1.16 | 1.30 | 1.34 |
| PRICE - SALES RATIO | - | - | 2.41 | 2.59 | 1.93 |
| PRICE - CASH FLOW RATIO | - | - | 5.47 | 7.58 | 12.16 |
Master Data
| WKN | 917165 |
| ISIN | DK0015998017 |
| SYMBOL | BV3 |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | Bavarian Nordic |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | Danish Krone |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | 77.14 Mil. |
| MARKET CAPITALISATION | 1.90 Bil. |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | 2.84 % | -7.37 % | 4.14 % | -2.30 % | 1.36 % | -14.62 % | -35.12 % | -2.76 % |
| HIGH | 24.98 | 26.74 | 27.22 | 27.22 | 32.76 | 42.80 | 56.40 | 27.22 |
| LOW | 23.68 | 23.68 | 23.54 | 23.54 | 22.18 | 16.95 | 15.55 | 23.54 |
Dividend
per share
Bavarian Nordic does not deliver dividend information
Company profile
Bavarian Nordic A/S engages in the business of developing, manufacturing, and commercializing cancer immunotherapies and vaccines for infectious diseases. The firm is involved in cancer immunotherapy including cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian, and prostate cancer. The company was founded on July 1, 1992 and is headquartered in Hellerup, Denmark.
Structured products for Bavarian Nordic AS
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.